Drug intelligence / Profile preview

CX-159X

Development stage: Preclinical
Lead developer: CarthroniX
Modality: Small Molecules
Administration: Oral

Overview

CX-159X is a preclinical-stage small molecule drug candidate being developed by CarthroniX. It is designed for oral administration and is currently being investigated for the treatment of idiopathic pulmonary fibrosis (IPF), systemic osteoarthritis, and veterinary oncology. The drug is part of CarthroniX's pipeline focusing on small molecule therapeutics for aging-related and inflammatory conditions. As of the latest available pipeline updates, CX-159X remains in the preclinical phase across all its primary indications.

Beyond the preview

Go deeper on CX-159X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CX-159X.

Explore the full profile